English

Astex Pharmaceuticals, Inc

EDGAR

Quarterly report (10-Q) · filed 2013-08-09

81 filing records in this dataset, filed from 1996-05-14 to 2013-08-09. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

16.6 million USD

2013 Q2 · USD

Exact inputs and evidence

Revenue: 16615000 USD Source

Operating margin

-42.8%

2013 Q2 · %

Exact inputs and evidence

Operating Income: -7112000 USD Source
Revenue: 16615000 USD Source

Operating cash flow

-5.4 million USD

2013 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -4049000 USD Source
Operating Cash Flow: 1347000 USD Source

Free cash flow

-6.03 million USD

2013 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -4049000 USD Source
Operating Cash Flow: 1347000 USD Source
Capital Expenditure: 923000 USD Source
Capital Expenditure: 291000 USD Source

Cash and cash equivalents: 35.6 million USD 2013-06-30 Source
Exact value

35644000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 94.9 million shares 2013-06-30 Source
Exact value

94934406 shares

Reported share-count change

1.85% · 1.72 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

93210324 shares · 2012-06-30· Source
94934406 shares · 2013-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

80 million USD

2012-07-01 – 2013-06-30

Exact inputs and evidence

Revenue: 17194000 USD · 2012-07-01 – 2012-09-30 Source
Revenue: 83159000 USD · 2012-01-01 – 2012-12-31 Source
Revenue: 59098000 USD · 2012-01-01 – 2012-09-30 Source
Revenue: 22089000 USD · 2013-01-01 – 2013-03-31 Source
Revenue: 16615000 USD · 2013-04-01 – 2013-06-30 Source

Net income

12.1 million USD

2010-10-01 – 2011-09-30

Exact inputs and evidence

Net income: 16273000 USD · 2010-01-01 – 2010-12-31 Source
Net income: 9527000 USD · 2010-01-01 – 2010-09-30 Source
Net income: 5490000 USD · 2011-01-01 – 2011-03-31 Source
Net income: 903000 USD · 2011-04-01 – 2011-06-30 Source
Net income: -1071000 USD · 2011-07-01 – 2011-09-30 Source

Operating cash flow

11.3 million USD

2012-07-01 – 2013-06-30

Exact inputs and evidence

Operating cash flow: 9587000 USD · 2012-01-01 – 2012-09-30 Source
Operating cash flow: 2646000 USD · 2012-01-01 – 2012-06-30 Source
Operating cash flow: 18021000 USD · 2012-01-01 – 2012-12-31 Source
Operating cash flow: 9587000 USD · 2012-01-01 – 2012-09-30 Source
Operating cash flow: 1347000 USD · 2013-01-01 – 2013-03-31 Source
Operating cash flow: -4049000 USD · 2013-01-01 – 2013-06-30 Source
Operating cash flow: 1347000 USD · 2013-01-01 – 2013-03-31 Source

Capital expenditure

1.25 million USD

2012-07-01 – 2013-06-30

Exact inputs and evidence

Capital expenditure: 872000 USD · 2012-01-01 – 2012-09-30 Source
Capital expenditure: 704000 USD · 2012-01-01 – 2012-06-30 Source
Capital expenditure: 1031000 USD · 2012-01-01 – 2012-12-31 Source
Capital expenditure: 872000 USD · 2012-01-01 – 2012-09-30 Source
Capital expenditure: 291000 USD · 2013-01-01 – 2013-03-31 Source
Capital expenditure: 923000 USD · 2013-01-01 – 2013-06-30 Source
Capital expenditure: 291000 USD · 2013-01-01 – 2013-03-31 Source

Free cash flow

10.1 million USD

2012-07-01 – 2013-06-30

Exact inputs and evidence

Operating cash flow: 9587000 USD · 2012-01-01 – 2012-09-30 Source
Operating cash flow: 2646000 USD · 2012-01-01 – 2012-06-30 Source
Operating cash flow: 18021000 USD · 2012-01-01 – 2012-12-31 Source
Operating cash flow: 9587000 USD · 2012-01-01 – 2012-09-30 Source
Operating cash flow: 1347000 USD · 2013-01-01 – 2013-03-31 Source
Operating cash flow: -4049000 USD · 2013-01-01 – 2013-06-30 Source
Operating cash flow: 1347000 USD · 2013-01-01 – 2013-03-31 Source
Capital expenditure: 872000 USD · 2012-01-01 – 2012-09-30 Source
Capital expenditure: 704000 USD · 2012-01-01 – 2012-06-30 Source
Capital expenditure: 1031000 USD · 2012-01-01 – 2012-12-31 Source
Capital expenditure: 872000 USD · 2012-01-01 – 2012-09-30 Source
Capital expenditure: 291000 USD · 2013-01-01 – 2013-03-31 Source
Capital expenditure: 923000 USD · 2013-01-01 – 2013-06-30 Source
Capital expenditure: 291000 USD · 2013-01-01 – 2013-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2013-08-09.

Financial data available through: 2012-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2012-12-31
Operating income: 11 of 11 periods available· newest 2012-12-31
Net income: 9 of 11 periods available· newest 2010-12-31
Operating cash flow: 11 of 11 periods available· newest 2012-12-31
Capital expenditure: 11 of 11 periods available· newest 2012-12-31
Total assets: 11 of 11 periods available· newest 2012-12-31
Total liabilities: 11 of 11 periods available· newest 2012-12-31
Current assets: 11 of 11 periods available· newest 2012-12-31
Current liabilities: 11 of 11 periods available· newest 2012-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2012-12-31
long term debt: No compatible figures in this window
Shares outstanding: 3 of 11 periods available· newest 2012-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+24.3%

Prior period

USD 66.91 million

2011-01-01 – 2011-12-31
Current period

USD 83.16 million

2012-01-01 – 2012-12-31

Exact inputs and evidence

83159000 − 66914000 = 16245000 USD

66914000 USD · 2011-01-01 – 2011-12-31
Inspect prior input Prior source
83159000 USD · 2012-01-01 – 2012-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Astex Pharmaceuticals, Inc · 2012-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Year-over-year change in Revenue: 16245000 USD Concept: fundies:Revenue Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 83159000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746913002974/astx-20121231.xml#154743 Filing: 000104746913002974 Input fundies:Revenue: 66914000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746913002974/astx-20121231.xml#154247 Filing: 000104746913002974
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+45.9%

Prior period

USD 12.35 million

2011-01-01 – 2011-12-31
Current period

USD 18.02 million

2012-01-01 – 2012-12-31

Exact inputs and evidence

18021000 − 12352000 = 5669000 USD

12352000 USD · 2011-01-01 – 2011-12-31
Inspect prior input Prior source
18021000 USD · 2012-01-01 – 2012-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Astex Pharmaceuticals, Inc · 2012-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Year-over-year change in Operating cash flow: 5669000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 18021000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746913002974/astx-20121231.xml#167770 Filing: 000104746913002974 Input fundies:OperatingCashFlow: 12352000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746913002974/astx-20121231.xml#167985 Filing: 000104746913002974
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-25.1%

Prior period

USD 1.38 million

2011-01-01 – 2011-12-31
Current period

USD 1.03 million

2012-01-01 – 2012-12-31

Exact inputs and evidence

1031000 − 1376000 = -345000 USD

1376000 USD · 2011-01-01 – 2011-12-31
Inspect prior input Prior source
1031000 USD · 2012-01-01 – 2012-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Astex Pharmaceuticals, Inc · 2012-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Year-over-year change in Capital expenditure: -345000 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1031000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746913002974/astx-20121231.xml#170012 Filing: 000104746913002974 Input fundies:CapitalExpenditure: 1376000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746913002974/astx-20121231.xml#170186 Filing: 000104746913002974
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Net income.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2012 2012-01-01 – 2012-12-31

Revenue USD 83.16 million 100% of revenue
Operating costs Derived USD 90.21 million 108% of revenue
Operating income −USD 7.05 million −8.5% of revenue
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow USD 18.02 million 22% of revenue
Capital expenditure USD 1.03 million 1.2% of revenue
Free cash flow Derived USD 16.99 million 20% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2003 Operating loss: operating costs were 475% of revenue.
2004 Operating loss: operating costs were 178% of revenue.
2005 Operating loss: operating costs were 153% of revenue.
2006 Operating loss: operating costs were 156% of revenue.
2007 Net income was higher than operating income, so the split is not drawn.
2008 Operating loss: operating costs were 122% of revenue.
2009 Net income was higher than operating income, so the split is not drawn.
2010 Net income was higher than operating income, so the split is not drawn.
2011 Not shown: operating income or net income is not reported.
2012 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2003 2003-01-01 – 2003-12-31	11494000	54613000 Derived	-43119000	10351000 Derived	-53470000	-36721000 Derived	Source 2003-01-01 – 2003-12-31: 11494000 USD Inspect Revenue Open source 2003-01-01 – 2003-12-31: -43119000 USD Inspect Operating Income Open source 2003-01-01 – 2003-12-31: -53470000 USD Inspect Net Income Open source 2003-01-01 – 2003-12-31: -36553000 USD Inspect Operating Cash Flow Open source 2003-01-01 – 2003-12-31: 168000 USD Inspect Capital Expenditure Open source
2004 2004-01-01 – 2004-12-31	31993000	56913000 Derived	-24920000	21940000 Derived	-46860000	-24814000 Derived	Source 2004-01-01 – 2004-12-31: 31993000 USD Inspect Revenue Open source 2004-01-01 – 2004-12-31: -24920000 USD Inspect Operating Income Open source 2004-01-01 – 2004-12-31: -46860000 USD Inspect Net Income Open source 2004-01-01 – 2004-12-31: -24541000 USD Inspect Operating Cash Flow Open source 2004-01-01 – 2004-12-31: 273000 USD Inspect Capital Expenditure Open source
2005 2005-01-01 – 2005-12-31	30169000	46156000 Derived	-15987000	-1505000 Derived	-14482000	-11765000 Derived	Source 2005-01-01 – 2005-12-31: 30169000 USD Inspect Revenue Open source 2005-01-01 – 2005-12-31: -15987000 USD Inspect Operating Income Open source 2005-01-01 – 2005-12-31: -14482000 USD Inspect Net Income Open source 2005-01-01 – 2005-12-31: -11659000 USD Inspect Operating Cash Flow Open source 2005-01-01 – 2005-12-31: 106000 USD Inspect Capital Expenditure Open source
2006 2006-01-01 – 2006-12-31	38083000	59579000 Derived	-21496000	-5009000 Derived	-16487000	6373000 Derived	Source 2006-01-01 – 2006-12-31: 38083000 USD Inspect Revenue Open source 2006-01-01 – 2006-12-31: -21496000 USD Inspect Operating Income Open source 2006-01-01 – 2006-12-31: -16487000 USD Inspect Net Income Open source 2006-01-01 – 2006-12-31: 7233000 USD Inspect Operating Cash Flow Open source 2006-01-01 – 2006-12-31: 860000 USD Inspect Capital Expenditure Open source
2007 2007-01-01 – 2007-12-31	22954000	13454000 Derived	9500000	-3581000 Derived	13081000	-7457000 Derived	Source 2007-01-01 – 2007-12-31: 22954000 USD Inspect Revenue Open source 2007-01-01 – 2007-12-31: 9500000 USD Inspect Operating Income Open source 2007-01-01 – 2007-12-31: 13081000 USD Inspect Net Income Open source 2007-01-01 – 2007-12-31: -5799000 USD Inspect Operating Cash Flow Open source 2007-01-01 – 2007-12-31: 1658000 USD Inspect Capital Expenditure Open source
2008 2008-01-01 – 2008-12-31	38422000	46753000 Derived	-8331000	780000 Derived	-9111000	-2798000 Derived	Source 2008-01-01 – 2008-12-31: 38422000 USD Inspect Revenue Open source 2008-01-01 – 2008-12-31: -8331000 USD Inspect Operating Income Open source 2008-01-01 – 2008-12-31: -9111000 USD Inspect Net Income Open source 2008-01-01 – 2008-12-31: -1662000 USD Inspect Operating Cash Flow Open source 2008-01-01 – 2008-12-31: 1136000 USD Inspect Capital Expenditure Open source
2009 2009-01-01 – 2009-12-31	41253000	38088000 Derived	3165000	-1572000 Derived	4737000	7704000 Derived	Source 2009-01-01 – 2009-12-31: 41253000 USD Inspect Revenue Open source 2009-01-01 – 2009-12-31: 3165000 USD Inspect Operating Income Open source 2009-01-01 – 2009-12-31: 4737000 USD Inspect Net Income Open source 2009-01-01 – 2009-12-31: 8693000 USD Inspect Operating Cash Flow Open source 2009-01-01 – 2009-12-31: 989000 USD Inspect Capital Expenditure Open source
2010 2010-01-01 – 2010-12-31	52972000	37086000 Derived	15886000	-387000 Derived	16273000	16989000 Derived	Source 2010-01-01 – 2010-12-31: 52972000 USD Inspect Revenue Open source 2010-01-01 – 2010-12-31: 15886000 USD Inspect Operating Income Open source 2010-01-01 – 2010-12-31: 16273000 USD Inspect Net Income Open source 2010-01-01 – 2010-12-31: 17996000 USD Inspect Operating Cash Flow Open source 2010-01-01 – 2010-12-31: 1007000 USD Inspect Capital Expenditure Open source
2011 2011-01-01 – 2011-12-31	66914000	64502000 Derived	2412000	Unavailable	Unavailable	10976000 Derived	Source 2011-01-01 – 2011-12-31: 66914000 USD Inspect Revenue Open source 2011-01-01 – 2011-12-31: 2412000 USD Inspect Operating Income Open source 2011-01-01 – 2011-12-31: 12352000 USD Inspect Operating Cash Flow Open source 2011-01-01 – 2011-12-31: 1376000 USD Inspect Capital Expenditure Open source
2012 2012-01-01 – 2012-12-31	83159000	90211000 Derived	-7052000	Unavailable	Unavailable	16990000 Derived	Source 2012-01-01 – 2012-12-31: 83159000 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: -7052000 USD Inspect Operating Income Open source 2012-01-01 – 2012-12-31: 18021000 USD Inspect Operating Cash Flow Open source 2012-01-01 – 2012-12-31: 1031000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 83.2M 2012

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20032003-12-31	Revenue	11494000	Revenue: 11494000 Open source
20042004-12-31	Revenue	31993000	Revenue: 31993000 Open source
20052005-12-31	Revenue	30169000	Revenue: 30169000 Open source
20062006-12-31	Revenue	38083000	Revenue: 38083000 Open source
20072007-12-31	Revenue	22954000	Revenue: 22954000 Open source
20082008-12-31	Revenue	38422000	Revenue: 38422000 Open source
20092009-12-31	Revenue	41253000	Revenue: 41253000 Open source
20102010-12-31	Revenue	52972000	Revenue: 52972000 Open source
20112011-12-31	Revenue	66914000	Revenue: 66914000 Open source
20122012-12-31	Revenue	83159000	Revenue: 83159000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

24.3% 2012

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20032003-12-31	Year over year	-24.7%	Revenue: 11494000 Open source Revenue: 15269000 Open source
20042004-12-31	Year over year	178.3%	Revenue: 31993000 Open source Revenue: 11494000 Open source
20052005-12-31	Year over year	-5.7%	Revenue: 30169000 Open source Revenue: 31993000 Open source
20062006-12-31	Year over year	26.2%	Revenue: 38083000 Open source Revenue: 30169000 Open source
20072007-12-31	Year over year	-39.7%	Revenue: 22954000 Open source Revenue: 38083000 Open source
20082008-12-31	Year over year	67.4%	Revenue: 38422000 Open source Revenue: 22954000 Open source
20092009-12-31	Year over year	7.4%	Revenue: 41253000 Open source Revenue: 38422000 Open source
20102010-12-31	Year over year	28.4%	Revenue: 52972000 Open source Revenue: 41253000 Open source
20112011-12-31	Year over year	26.3%	Revenue: 66914000 Open source Revenue: 52972000 Open source
20122012-12-31	Year over year	24.3%	Revenue: 83159000 Open source Revenue: 66914000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -8.5% 2012

Net margin 30.7% 2010

Free cash flow margin 20.4% 2012

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20032003-12-31	Operating margin	-375.1%	Operating Income: -43119000 Open source Revenue: 11494000 Open source
20042004-12-31	Operating margin	-77.9%	Operating Income: -24920000 Open source Revenue: 31993000 Open source
20052005-12-31	Operating margin	-53%	Operating Income: -15987000 Open source Revenue: 30169000 Open source
20062006-12-31	Operating margin	-56.4%	Operating Income: -21496000 Open source Revenue: 38083000 Open source
20072007-12-31	Operating margin	41.4%	Operating Income: 9500000 Open source Revenue: 22954000 Open source
20082008-12-31	Operating margin	-21.7%	Operating Income: -8331000 Open source Revenue: 38422000 Open source
20092009-12-31	Operating margin	7.7%	Operating Income: 3165000 Open source Revenue: 41253000 Open source
20102010-12-31	Operating margin	30%	Operating Income: 15886000 Open source Revenue: 52972000 Open source
20112011-12-31	Operating margin	3.6%	Operating Income: 2412000 Open source Revenue: 66914000 Open source
20122012-12-31	Operating margin	-8.5%	Operating Income: -7052000 Open source Revenue: 83159000 Open source
20032003-12-31	Net margin	-465.2%	Net Income: -53470000 Open source Revenue: 11494000 Open source
20042004-12-31	Net margin	-146.5%	Net Income: -46860000 Open source Revenue: 31993000 Open source
20052005-12-31	Net margin	-48%	Net Income: -14482000 Open source Revenue: 30169000 Open source
20062006-12-31	Net margin	-43.3%	Net Income: -16487000 Open source Revenue: 38083000 Open source
20072007-12-31	Net margin	57%	Net Income: 13081000 Open source Revenue: 22954000 Open source
20082008-12-31	Net margin	-23.7%	Net Income: -9111000 Open source Revenue: 38422000 Open source
20092009-12-31	Net margin	11.5%	Net Income: 4737000 Open source Revenue: 41253000 Open source
20102010-12-31	Net margin	30.7%	Net Income: 16273000 Open source Revenue: 52972000 Open source
2011-12-31	Net margin	Not reported	Revenue: 66914000 Open source
2012-12-31	Net margin	Not reported	Revenue: 83159000 Open source
20032003-12-31	Free cash flow margin	-319.5%	Revenue: 11494000 Open source Operating Cash Flow: -36553000 Open source Capital Expenditure: 168000 Open source
20042004-12-31	Free cash flow margin	-77.6%	Revenue: 31993000 Open source Operating Cash Flow: -24541000 Open source Capital Expenditure: 273000 Open source
20052005-12-31	Free cash flow margin	-39%	Revenue: 30169000 Open source Operating Cash Flow: -11659000 Open source Capital Expenditure: 106000 Open source
20062006-12-31	Free cash flow margin	16.7%	Revenue: 38083000 Open source Operating Cash Flow: 7233000 Open source Capital Expenditure: 860000 Open source
20072007-12-31	Free cash flow margin	-32.5%	Revenue: 22954000 Open source Operating Cash Flow: -5799000 Open source Capital Expenditure: 1658000 Open source
20082008-12-31	Free cash flow margin	-7.3%	Revenue: 38422000 Open source Operating Cash Flow: -1662000 Open source Capital Expenditure: 1136000 Open source
20092009-12-31	Free cash flow margin	18.7%	Revenue: 41253000 Open source Operating Cash Flow: 8693000 Open source Capital Expenditure: 989000 Open source
20102010-12-31	Free cash flow margin	32.1%	Revenue: 52972000 Open source Operating Cash Flow: 17996000 Open source Capital Expenditure: 1007000 Open source
20112011-12-31	Free cash flow margin	16.4%	Revenue: 66914000 Open source Operating Cash Flow: 12352000 Open source Capital Expenditure: 1376000 Open source
20122012-12-31	Free cash flow margin	20.4%	Revenue: 83159000 Open source Operating Cash Flow: 18021000 Open source Capital Expenditure: 1031000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 18M 2012

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20032003-12-31	Operating cash flow	-36553000	Operating Cash Flow: -36553000 Open source
20042004-12-31	Operating cash flow	-24541000	Operating Cash Flow: -24541000 Open source
20052005-12-31	Operating cash flow	-11659000	Operating Cash Flow: -11659000 Open source
20062006-12-31	Operating cash flow	7233000	Operating Cash Flow: 7233000 Open source
20072007-12-31	Operating cash flow	-5799000	Operating Cash Flow: -5799000 Open source
20082008-12-31	Operating cash flow	-1662000	Operating Cash Flow: -1662000 Open source
20092009-12-31	Operating cash flow	8693000	Operating Cash Flow: 8693000 Open source
20102010-12-31	Operating cash flow	17996000	Operating Cash Flow: 17996000 Open source
20112011-12-31	Operating cash flow	12352000	Operating Cash Flow: 12352000 Open source
20122012-12-31	Operating cash flow	18021000	Operating Cash Flow: 18021000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 17M 2012

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20032003-12-31	Free cash flow	-36721000	Operating Cash Flow: -36553000 Open source Capital Expenditure: 168000 Open source
20042004-12-31	Free cash flow	-24814000	Operating Cash Flow: -24541000 Open source Capital Expenditure: 273000 Open source
20052005-12-31	Free cash flow	-11765000	Operating Cash Flow: -11659000 Open source Capital Expenditure: 106000 Open source
20062006-12-31	Free cash flow	6373000	Operating Cash Flow: 7233000 Open source Capital Expenditure: 860000 Open source
20072007-12-31	Free cash flow	-7457000	Operating Cash Flow: -5799000 Open source Capital Expenditure: 1658000 Open source
20082008-12-31	Free cash flow	-2798000	Operating Cash Flow: -1662000 Open source Capital Expenditure: 1136000 Open source
20092009-12-31	Free cash flow	7704000	Operating Cash Flow: 8693000 Open source Capital Expenditure: 989000 Open source
20102010-12-31	Free cash flow	16989000	Operating Cash Flow: 17996000 Open source Capital Expenditure: 1007000 Open source
20112011-12-31	Free cash flow	10976000	Operating Cash Flow: 12352000 Open source Capital Expenditure: 1376000 Open source
20122012-12-31	Free cash flow	16990000	Operating Cash Flow: 18021000 Open source Capital Expenditure: 1031000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

13.9% 2012

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20032003-12-31	Liabilities / assets	51%	Total Liabilities: 27889000 Open source Total Assets: 54736000 Open source
20042004-12-31	Liabilities / assets	22.7%	Total Liabilities: 21444000 Open source Total Assets: 94657000 Open source
20052005-12-31	Liabilities / assets	12.3%	Total Liabilities: 9014000 Open source Total Assets: 73271000 Open source
20062006-12-31	Liabilities / assets	25.2%	Total Liabilities: 22214000 Open source Total Assets: 88046000 Open source
20072007-12-31	Liabilities / assets	7.8%	Total Liabilities: 7793000 Open source Total Assets: 100448000 Open source
20082008-12-31	Liabilities / assets	7.4%	Total Liabilities: 7274000 Open source Total Assets: 97765000 Open source
20092009-12-31	Liabilities / assets	7.7%	Total Liabilities: 8531000 Open source Total Assets: 110517000 Open source
20102010-12-31	Liabilities / assets	5.8%	Total Liabilities: 7486000 Open source Total Assets: 129098000 Open source
20112011-12-31	Liabilities / assets	20.6%	Total Liabilities: 56947000 Open source Total Assets: 276948000 Open source
20122012-12-31	Liabilities / assets	13.9%	Total Liabilities: 38222000 Open source Total Assets: 275164000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

7.46× 2012

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20032003-12-31	Current assets / current liabilities	1.27×	Current Assets: 32230000 Open source Current Liabilities: 25414000 Open source
20042004-12-31	Current assets / current liabilities	3.85×	Current Assets: 79073000 Open source Current Liabilities: 20517000 Open source
20052005-12-31	Current assets / current liabilities	7.04×	Current Assets: 56636000 Open source Current Liabilities: 8042000 Open source
20062006-12-31	Current assets / current liabilities	3.37×	Current Assets: 71688000 Open source Current Liabilities: 21276000 Open source
20072007-12-31	Current assets / current liabilities	12.68×	Current Assets: 88287000 Open source Current Liabilities: 6961000 Open source
20082008-12-31	Current assets / current liabilities	12.72×	Current Assets: 88002000 Open source Current Liabilities: 6916000 Open source
20092009-12-31	Current assets / current liabilities	15.1×	Current Assets: 99251000 Open source Current Liabilities: 6573000 Open source
20102010-12-31	Current assets / current liabilities	19.25×	Current Assets: 116623000 Open source Current Liabilities: 6057000 Open source
20112011-12-31	Current assets / current liabilities	3.94×	Current Assets: 136570000 Open source Current Liabilities: 34670000 Open source
20122012-12-31	Current assets / current liabilities	7.46×	Current Assets: 146507000 Open source Current Liabilities: 19640000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2003 2003-01-01 – 2003-12-31	−USD 53.47 million Exact value Exact value: -53470000 USD 2003-01-01 – 2003-12-31: -53470000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Astex Pharmaceuticals, Inc · 2003-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Net Income: -53470000 USD Concept: fundies:NetIncome Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3ANetIncome&period=2003-12-31&surface=latest&period_type=duration&start=2003-01-01&unit=USD&dimensions= Input fundies:NetIncome: -53470000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001104659-06-017211.txt#16833 The citation records this snapshot. The page link may show a newer release later.	−USD 36.55 million Exact value Exact value: -36553000 USD 2003-01-01 – 2003-12-31: -36553000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Astex Pharmaceuticals, Inc · 2003-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Operating Cash Flow: -36553000 USD Concept: fundies:OperatingCashFlow Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3AOperatingCashFlow&period=2003-12-31&surface=latest&period_type=duration&start=2003-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -36553000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001104659-06-017211.txt#17472 The citation records this snapshot. The page link may show a newer release later.	USD 168,000 Exact value Exact value: 168000 USD 2003-01-01 – 2003-12-31: 168000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Astex Pharmaceuticals, Inc · 2003-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Capital Expenditure: 168000 USD Concept: fundies:CapitalExpenditure Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3ACapitalExpenditure&period=2003-12-31&surface=latest&period_type=duration&start=2003-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 168000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001104659-06-017211.txt#17657 The citation records this snapshot. The page link may show a newer release later.	−USD 36.72 million Calculation and evidence -36553000 − 168000 USD Exact free cash flow: -36721000 USD 2003-01-01 – 2003-12-31: -36553000 USD · Inspect Operating Cash Flow · Source 2003-01-01 – 2003-12-31: 168000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Astex Pharmaceuticals, Inc · 2003-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Free cash flow: -36721000 USD Concept: free-cash-flow Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -36553000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001104659-06-017211.txt#17472 Input fundies:CapitalExpenditure: 168000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001104659-06-017211.txt#17657 The citation records this snapshot. The page link may show a newer release later.
2004 2004-01-01 – 2004-12-31	−USD 46.86 million Exact value Exact value: -46860000 USD 2004-01-01 – 2004-12-31: -46860000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Astex Pharmaceuticals, Inc · 2004-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Net Income: -46860000 USD Concept: fundies:NetIncome Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3ANetIncome&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:NetIncome: -46860000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001104659-07-020098.txt#16624 The citation records this snapshot. The page link may show a newer release later.	−USD 24.54 million Exact value Exact value: -24541000 USD 2004-01-01 – 2004-12-31: -24541000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Astex Pharmaceuticals, Inc · 2004-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Operating Cash Flow: -24541000 USD Concept: fundies:OperatingCashFlow Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3AOperatingCashFlow&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -24541000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001104659-07-020098.txt#17316 The citation records this snapshot. The page link may show a newer release later.	USD 273,000 Exact value Exact value: 273000 USD 2004-01-01 – 2004-12-31: 273000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Astex Pharmaceuticals, Inc · 2004-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Capital Expenditure: 273000 USD Concept: fundies:CapitalExpenditure Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3ACapitalExpenditure&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 273000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001104659-07-020098.txt#17420 The citation records this snapshot. The page link may show a newer release later.	−USD 24.81 million Calculation and evidence -24541000 − 273000 USD Exact free cash flow: -24814000 USD 2004-01-01 – 2004-12-31: -24541000 USD · Inspect Operating Cash Flow · Source 2004-01-01 – 2004-12-31: 273000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Astex Pharmaceuticals, Inc · 2004-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Free cash flow: -24814000 USD Concept: free-cash-flow Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -24541000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001104659-07-020098.txt#17316 Input fundies:CapitalExpenditure: 273000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001104659-07-020098.txt#17420 The citation records this snapshot. The page link may show a newer release later.
2005 2005-01-01 – 2005-12-31	−USD 14.48 million Exact value Exact value: -14482000 USD 2005-01-01 – 2005-12-31: -14482000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Astex Pharmaceuticals, Inc · 2005-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Net Income: -14482000 USD Concept: fundies:NetIncome Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3ANetIncome&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14482000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-08-002935.txt#6792 The citation records this snapshot. The page link may show a newer release later.	−USD 11.66 million Exact value Exact value: -11659000 USD 2005-01-01 – 2005-12-31: -11659000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Astex Pharmaceuticals, Inc · 2005-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Operating Cash Flow: -11659000 USD Concept: fundies:OperatingCashFlow Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3AOperatingCashFlow&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -11659000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-08-002935.txt#7137 The citation records this snapshot. The page link may show a newer release later.	USD 106,000 Exact value Exact value: 106000 USD 2005-01-01 – 2005-12-31: 106000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Astex Pharmaceuticals, Inc · 2005-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Capital Expenditure: 106000 USD Concept: fundies:CapitalExpenditure Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3ACapitalExpenditure&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 106000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-08-002935.txt#7201 The citation records this snapshot. The page link may show a newer release later.	−USD 11.77 million Calculation and evidence -11659000 − 106000 USD Exact free cash flow: -11765000 USD 2005-01-01 – 2005-12-31: -11659000 USD · Inspect Operating Cash Flow · Source 2005-01-01 – 2005-12-31: 106000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Astex Pharmaceuticals, Inc · 2005-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Free cash flow: -11765000 USD Concept: free-cash-flow Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -11659000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-08-002935.txt#7137 Input fundies:CapitalExpenditure: 106000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-08-002935.txt#7201 The citation records this snapshot. The page link may show a newer release later.
2006 2006-01-01 – 2006-12-31	−USD 16.49 million Exact value Exact value: -16487000 USD 2006-01-01 – 2006-12-31: -16487000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Astex Pharmaceuticals, Inc · 2006-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Net Income: -16487000 USD Concept: fundies:NetIncome Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3ANetIncome&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16487000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-09-002736.txt#7660 The citation records this snapshot. The page link may show a newer release later.	USD 7.23 million Exact value Exact value: 7233000 USD 2006-01-01 – 2006-12-31: 7233000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Astex Pharmaceuticals, Inc · 2006-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Operating Cash Flow: 7233000 USD Concept: fundies:OperatingCashFlow Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3AOperatingCashFlow&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 7233000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-09-002736.txt#7960 The citation records this snapshot. The page link may show a newer release later.	USD 860,000 Exact value Exact value: 860000 USD 2006-01-01 – 2006-12-31: 860000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Astex Pharmaceuticals, Inc · 2006-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Capital Expenditure: 860000 USD Concept: fundies:CapitalExpenditure Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3ACapitalExpenditure&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 860000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-09-002736.txt#8024 The citation records this snapshot. The page link may show a newer release later.	USD 6.37 million Calculation and evidence 7233000 − 860000 USD Exact free cash flow: 6373000 USD 2006-01-01 – 2006-12-31: 7233000 USD · Inspect Operating Cash Flow · Source 2006-01-01 – 2006-12-31: 860000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Astex Pharmaceuticals, Inc · 2006-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Free cash flow: 6373000 USD Concept: free-cash-flow Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 7233000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-09-002736.txt#7960 Input fundies:CapitalExpenditure: 860000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-09-002736.txt#8024 The citation records this snapshot. The page link may show a newer release later.
2007 2007-01-01 – 2007-12-31	USD 13.08 million Exact value Exact value: 13081000 USD 2007-01-01 – 2007-12-31: 13081000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Astex Pharmaceuticals, Inc · 2007-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Net Income: 13081000 USD Concept: fundies:NetIncome Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3ANetIncome&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:NetIncome: 13081000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-10-002198.txt#7421 The citation records this snapshot. The page link may show a newer release later.	−USD 5.8 million Exact value Exact value: -5799000 USD 2007-01-01 – 2007-12-31: -5799000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Astex Pharmaceuticals, Inc · 2007-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Operating Cash Flow: -5799000 USD Concept: fundies:OperatingCashFlow Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3AOperatingCashFlow&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5799000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-10-002198.txt#7692 The citation records this snapshot. The page link may show a newer release later.	USD 1.66 million Exact value Exact value: 1658000 USD 2007-01-01 – 2007-12-31: 1658000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Astex Pharmaceuticals, Inc · 2007-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Capital Expenditure: 1658000 USD Concept: fundies:CapitalExpenditure Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3ACapitalExpenditure&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1658000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-10-002198.txt#7756 The citation records this snapshot. The page link may show a newer release later.	−USD 7.46 million Calculation and evidence -5799000 − 1658000 USD Exact free cash flow: -7457000 USD 2007-01-01 – 2007-12-31: -5799000 USD · Inspect Operating Cash Flow · Source 2007-01-01 – 2007-12-31: 1658000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Astex Pharmaceuticals, Inc · 2007-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Free cash flow: -7457000 USD Concept: free-cash-flow Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5799000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-10-002198.txt#7692 Input fundies:CapitalExpenditure: 1658000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-10-002198.txt#7756 The citation records this snapshot. The page link may show a newer release later.
2008 2008-01-01 – 2008-12-31	−USD 9.11 million Exact value Exact value: -9111000 USD 2008-01-01 – 2008-12-31: -9111000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Astex Pharmaceuticals, Inc · 2008-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Net Income: -9111000 USD Concept: fundies:NetIncome Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3ANetIncome&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9111000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-11-001902.txt#7497 The citation records this snapshot. The page link may show a newer release later.	−USD 1.66 million Exact value Exact value: -1662000 USD 2008-01-01 – 2008-12-31: -1662000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Astex Pharmaceuticals, Inc · 2008-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Operating Cash Flow: -1662000 USD Concept: fundies:OperatingCashFlow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3AOperatingCashFlow&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1662000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-11-001902.txt#7752 The citation records this snapshot. The page link may show a newer release later.	USD 1.14 million Exact value Exact value: 1136000 USD 2008-01-01 – 2008-12-31: 1136000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Astex Pharmaceuticals, Inc · 2008-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Capital Expenditure: 1136000 USD Concept: fundies:CapitalExpenditure Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3ACapitalExpenditure&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1136000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-11-001902.txt#7816 The citation records this snapshot. The page link may show a newer release later.	−USD 2.8 million Calculation and evidence -1662000 − 1136000 USD Exact free cash flow: -2798000 USD 2008-01-01 – 2008-12-31: -1662000 USD · Inspect Operating Cash Flow · Source 2008-01-01 – 2008-12-31: 1136000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Astex Pharmaceuticals, Inc · 2008-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Free cash flow: -2798000 USD Concept: free-cash-flow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1662000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-11-001902.txt#7752 Input fundies:CapitalExpenditure: 1136000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-11-001902.txt#7816 The citation records this snapshot. The page link may show a newer release later.
2009 2009-01-01 – 2009-12-31	USD 4.74 million Exact value Exact value: 4737000 USD 2009-01-01 – 2009-12-31: 4737000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Astex Pharmaceuticals, Inc · 2009-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Net Income: 4737000 USD Concept: fundies:NetIncome Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3ANetIncome&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:NetIncome: 4737000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-11-001902.txt#7497 The citation records this snapshot. The page link may show a newer release later.	USD 8.69 million Exact value Exact value: 8693000 USD 2009-01-01 – 2009-12-31: 8693000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Astex Pharmaceuticals, Inc · 2009-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Operating Cash Flow: 8693000 USD Concept: fundies:OperatingCashFlow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3AOperatingCashFlow&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 8693000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746912002753/astx-20111231.xml#48594 Filing: 000104746912002753 The citation records this snapshot. The page link may show a newer release later.	USD 989,000 Exact value Exact value: 989000 USD 2009-01-01 – 2009-12-31: 989000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Astex Pharmaceuticals, Inc · 2009-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Capital Expenditure: 989000 USD Concept: fundies:CapitalExpenditure Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3ACapitalExpenditure&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 989000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746912002753/astx-20111231.xml#52955 Filing: 000104746912002753 The citation records this snapshot. The page link may show a newer release later.	USD 7.7 million Calculation and evidence 8693000 − 989000 USD Exact free cash flow: 7704000 USD 2009-01-01 – 2009-12-31: 8693000 USD · Inspect Operating Cash Flow · Source 2009-01-01 – 2009-12-31: 989000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Astex Pharmaceuticals, Inc · 2009-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Free cash flow: 7704000 USD Concept: free-cash-flow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 8693000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746912002753/astx-20111231.xml#48594 Filing: 000104746912002753 Input fundies:CapitalExpenditure: 989000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746912002753/astx-20111231.xml#52955 Filing: 000104746912002753 The citation records this snapshot. The page link may show a newer release later.
2010 2010-01-01 – 2010-12-31	USD 16.27 million Exact value Exact value: 16273000 USD 2010-01-01 – 2010-12-31: 16273000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Astex Pharmaceuticals, Inc · 2010-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Net Income: 16273000 USD Concept: fundies:NetIncome Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3ANetIncome&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:NetIncome: 16273000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/0001047469-11-001902.txt#7497 The citation records this snapshot. The page link may show a newer release later.	USD 18 million Exact value Exact value: 17996000 USD 2010-01-01 – 2010-12-31: 17996000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Astex Pharmaceuticals, Inc · 2010-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Operating Cash Flow: 17996000 USD Concept: fundies:OperatingCashFlow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3AOperatingCashFlow&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 17996000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746913002974/astx-20121231.xml#168200 Filing: 000104746913002974 The citation records this snapshot. The page link may show a newer release later.	USD 1.01 million Exact value Exact value: 1007000 USD 2010-01-01 – 2010-12-31: 1007000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Astex Pharmaceuticals, Inc · 2010-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Capital Expenditure: 1007000 USD Concept: fundies:CapitalExpenditure Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3ACapitalExpenditure&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1007000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746913002974/astx-20121231.xml#170360 Filing: 000104746913002974 The citation records this snapshot. The page link may show a newer release later.	USD 16.99 million Calculation and evidence 17996000 − 1007000 USD Exact free cash flow: 16989000 USD 2010-01-01 – 2010-12-31: 17996000 USD · Inspect Operating Cash Flow · Source 2010-01-01 – 2010-12-31: 1007000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Astex Pharmaceuticals, Inc · 2010-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Free cash flow: 16989000 USD Concept: free-cash-flow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 17996000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746913002974/astx-20121231.xml#168200 Filing: 000104746913002974 Input fundies:CapitalExpenditure: 1007000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746913002974/astx-20121231.xml#170360 Filing: 000104746913002974 The citation records this snapshot. The page link may show a newer release later.
2011 2011-01-01 – 2011-12-31	Unavailable Not reported for this period.	USD 12.35 million Exact value Exact value: 12352000 USD 2011-01-01 – 2011-12-31: 12352000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Astex Pharmaceuticals, Inc · 2011-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Operating Cash Flow: 12352000 USD Concept: fundies:OperatingCashFlow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3AOperatingCashFlow&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 12352000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746913002974/astx-20121231.xml#167985 Filing: 000104746913002974 The citation records this snapshot. The page link may show a newer release later.	USD 1.38 million Exact value Exact value: 1376000 USD 2011-01-01 – 2011-12-31: 1376000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Astex Pharmaceuticals, Inc · 2011-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Capital Expenditure: 1376000 USD Concept: fundies:CapitalExpenditure Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3ACapitalExpenditure&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1376000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746913002974/astx-20121231.xml#170186 Filing: 000104746913002974 The citation records this snapshot. The page link may show a newer release later.	USD 10.98 million Calculation and evidence 12352000 − 1376000 USD Exact free cash flow: 10976000 USD 2011-01-01 – 2011-12-31: 12352000 USD · Inspect Operating Cash Flow · Source 2011-01-01 – 2011-12-31: 1376000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Astex Pharmaceuticals, Inc · 2011-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Free cash flow: 10976000 USD Concept: free-cash-flow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 12352000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746913002974/astx-20121231.xml#167985 Filing: 000104746913002974 Input fundies:CapitalExpenditure: 1376000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746913002974/astx-20121231.xml#170186 Filing: 000104746913002974 The citation records this snapshot. The page link may show a newer release later.
2012 2012-01-01 – 2012-12-31	Unavailable Not reported for this period.	USD 18.02 million Exact value Exact value: 18021000 USD 2012-01-01 – 2012-12-31: 18021000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Astex Pharmaceuticals, Inc · 2012-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Operating Cash Flow: 18021000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 18021000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746913002974/astx-20121231.xml#167770 Filing: 000104746913002974 The citation records this snapshot. The page link may show a newer release later.	USD 1.03 million Exact value Exact value: 1031000 USD 2012-01-01 – 2012-12-31: 1031000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Astex Pharmaceuticals, Inc · 2012-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Capital Expenditure: 1031000 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1031000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746913002974/astx-20121231.xml#170012 Filing: 000104746913002974 The citation records this snapshot. The page link may show a newer release later.	USD 16.99 million Calculation and evidence 18021000 − 1031000 USD Exact free cash flow: 16990000 USD 2012-01-01 – 2012-12-31: 18021000 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 1031000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Astex Pharmaceuticals, Inc · 2012-12-31 Astex Pharmaceuticals, Inc (edgar:919722) Free cash flow: 16990000 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T21:36:48Z Snapshot: c0b60fdae313a1b419f11460d397d1b3e5b9cd8d3c8faf812f8c500ae9b20e81 Dimensions: Consolidated View: https://fundies.io/companies/edgar/919722?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 18021000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746913002974/astx-20121231.xml#167770 Filing: 000104746913002974 Input fundies:CapitalExpenditure: 1031000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/919722/000104746913002974/astx-20121231.xml#170012 Filing: 000104746913002974 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

81 filings · 720 latest values · 720 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000919722, 919722, edgar:919722

Also known as Astex Pharmaceuticals, Inc, SUPERGEN INC

Astex Pharmaceuticals, Inc

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Operating cash flow

Capital expenditure

Where revenue goes

2012 2012-01-01 – 2012-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation